Evaluation of the pharmacokinetics of the simultaneous quantification of letrozole and palbociclib in rat plasma by a developed and validated HPLC–PDA

• Autorzy: Al-Shehri Mona , Hefnawy Mohamed , Abuelizz Hatem , Alzamil Adeeba

Identyfikatory

DOI

10.1556/1326.2019.00635

• Języki publikacji: EN

Abstrakty

EN

The US Food and Drug Administration (FDA) has affirmed the use of letrozole (LTZ combined with palbociclib (PLB) to treat breast malignant tumor growth in postmenopausal women. A straightforward and extremely sensitive reversed-phase high-performance liquid chromatography method with photodiode array detection (RP-HPLC–PDA) was created and validated for the simultaneous determination of LTZ and PLB in rat plasma. The parameters used to give the best separation were a C18 column (150 mm × 4.6 mm, 3.5 μm) as the stationary phase with an isocratic mobile phase composed of methanol–30 mM ammonium acetate at a ratio of 60:40 (v/v), pH = 5.5, a flow rate of 0.8 mL/min, and detection wavelengths of 240 and 220 nm for LTZ and PLB, respectively. The developed method was assessed by the FDA rules over a range of 10–600 ng/mL for LTZ and PLB. The mean of %recovery of LTZ and PLB extracted from rat plasma by acetonitrile-based deproteinization was 91.06 ± 2.73 and 90.30 ± 1.95%, respectively, and the limits of detection were 5 ng/mL for LTZ and 7 ng/mL for PLB in rat plasma. The mean values of Tmax and Cmax were 6 ± 0.00 h and 266.96 ± 21.23 ng/mL for LTZ and 4 ± 0.00 h and 508.75 ± 61.56 ng/mL for PBL, respectively, after intraperitoneal administration of both drugs to rats. The developed HPLC–PDA method was demonstrated to be robust and was effectively applied to study the pharmacokinetics of LTZ and PLB in rat plasma.

Słowa kluczowe

EN

letrozole; palbociclib; HPLC-PDA; simulateonous quantification; pharmacokinetics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2020
• Tom: Vol. 32, no. 3
• Strony: 170--178
• Opis fizyczny: Bibliogr. 60 poz., rys., tab.

Twórcy

autor

Al-Shehri Mona

• Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

autor

Hefnawy Mohamed

• Department of Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

autor

Abuelizz Hatem

• Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

autor

Alzamil Adeeba

• Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

Bibliografia

• [1] Siegel, R.; Miller, K.; Jemal, A. Cancer J. Clin. 2017, 67, 7–30.
• [2] Lu J. J. Hematol. Oncol. 2015, 8, 1–3.
• [3] Finn, R.; Crown, J.; Lang, I.; Boer, K.; Bondarenko, I.; Kulyk, S.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; Shparyk, Y.; Thummala, A.; Voytko, N.; Fowst, C.; Huang, X.; Kim, S.; Randolph, S.; Slamon, D. Lancet Oncol. 2015, 16, 25–35.
• [4] Finn, R.; Martin, M.; Rugo, H.; Jones, S.; Im, S.; Gelmon, K.; Harbeck, N.; Lipatov, O.; Walshe, J.; Moulder, S.; Gauthier, E.; Lu, D.; Randolph, S.; Diéras, V.; Slamon, D. N. Eng. J. Med. 2016, 375, 1925–1936.
• [5] http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549978.htm. Retrieved 15, Feb., 2019.
• [6] Asghar, U.; Witkiewicz, A.; Turner, N.; Knudsen, E. Nat. Rev. Drug Disc. 2015, 14, 130–146.
• [7] Shah, A.; Cristofanilli, M. Curr. Treat Options Oncol. 2017, 18, 6.
• [8] Sablin, M.; Ricci, F.; Loirat, D.; Jobard, A.; Basse, C.; Romano, E.; Tourneau, C.; Dieras, V. Bull. Cancer 2017, 104, 114–122.
• [9] Xu, H.; Yu, S.; Liu, Q.; Yuan, X.; Mani, S.; Pestell, R.; Wu, K. J. Hematol. Oncol. 2017, 10, 97.
• [10] Ehab, M.; Elba, M. Breast Cancer 2016, 8, 83–91.
• [11] Chavana, B.; Tiwaria, S.; Shankarb, G.; Nimbalkarc, R.; Gargc, P.; Srinivasab, R.; Talluri, M. J. Pharm. Biomed. Anal. 2018, 157, 59–57.
• [12] Letrozole (Femara® tablets) https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020726s018lbl.pdf. Retrieved 2, Feb., 2019
• [13] Novartis Pharmaceuticals Canada Inc , FEMARA® product monograph, Dorval, Quebec, 2008.
• [14] Aman, U.; Buzdar, M.; John, F.; Robertson, M.; Wolfgang Eiermann, M.; Jean-Marc Nabholtz, M. Cancer 2002, 95, 2006–16.
• [15] Acharjya, S.; Mallick, P.; Panda, P.; Kumar, K.; Annapurna, M. J. Adv. Pharm. Tech. Res. 2010, 1, 348–435.
• [16] Ganesh, M.; Kamalakannan, K.; Patil, R.; Upadhyay, S.; Srivatsava, A.; Sivakumar, T. Rasayan J Chem. 2008, 1, 155–158.
• [17] Mondal, N.; Pal, T.; Ghosal, S. Pharmazie 2007, 62, 597–598.
• [18] Shrivastava, A.; Chakraborty, A.; Rambhade, S.; Patil, U. Pharm. Sin. 2011, 2, 263–269.
• [19] Ganesh, M.; Rajasekar, K.; Bhagiyalakshmi, M.; Vinoba, M.; Saktimanigandan, K.; Jang, H. Trop. J. Pharm. Res. 2010, 9, 505–510.
• [20] Pallavi, S.; Vasanth, P.; Ramesh, T.; Malothu, R. Int. Res. J. Pharm. 2012, 3, 202–204.
• [21] Nataraj, K.; Kiran, K.; Ravinder, R.; Kesinath, R.; Vrushabendra, S. Res. J. Pharm. Biol. Chem. Sci. 2012, 3, 658–676.
• [22] Sekar, V.; Jayaseelan, S.; Subash, N.; Kumar, E.; Perumal, P.; Venkatesh, R.; Sekar, M. Int. J. Pharm. Res. Dev. 2009, 1, 1–7.
• [23] Laha, T.; Patnaik, R.; Sen, S. Indian J. Pharm. Sci. 2008, 70, 401–403.
• [24] Mondal, N.; Pal, T.; Ghosal, S. Acta Pol. Pharm. 2009, 66, 11–17.
• [25] Pfister, C.; Duval, M.; Godbillon, J.; Gosset, G.; Gygax, D.; Marfil, F.; Sioufi, A.; Winkler, B. J. Pharm. Sci. 1994, 83, 520–524.
• [26] Ping, G.; Yuru. L.; Yuxia, W.; Sumei, J. Chin. J. Pharm. 2001, 7, 317–318.
• [27] Acharjya, S.; Bhattamisra, S.; Muddana, B.; Bera, R.; Panda, B.; Mishra, G. Sci. Pharm. 2012, 80, 941–953.
• [28] Berzas, J.; Rodriguez, J.; Contento, A.; Cabello, M. J. Sep. Sci. 2003, 26, 908–914.
• [29] Rodríguez-Flores, J.; Salcedo, A.; Llerena, M.; Fernández, L. J. Chromatogr. A 2008, 1185, 281–290.
• [30] Rodríguez-Flores, J.; Contento Salcedo, A.; Villaseñor Llerena, M.; Muñoz Fernández, L. Electrophoresis 2008, 29, 811–818.
• [31] Flores, J.; Salcedo, A.; Fernández, L. Anal. Chem. Insight. 2008, 3, 91–101.
• [32] Rodríguez-Flores, J.; Contento-Salcedo, A.; Muñoz Fernández, L. Electrophoresis 2009, 30, 624–632.
• [33] Rodríguez, J.; Castañeda, G.; Muñoz, L. J. Chromatogr. B 2013, 913-914, 12–18.
• [34] Moussa, B.; El-Bagary, R.; Osman, E.; Anal. Chem. Lett. 2013, 3, 139–146.
• [35] Zarghi, A.; Foroutan, S.; Shafaati, A.; Khoddam, A. Chromatographia 2007, 66, 747–750.
• [36] Marfil, F.; Pineau, V.; Sioufi, A.; Godbillon, S, J. Chromatogr. B Biomed. Sci. Appl. 1996, 683, 251–258.
• [37] Joshi, C.; Vishnubhatla, S.; Chakkirala, S.; Manama, S. Asian J. Pharm. Clin. Res. 2011, 4, 107–112.
• [38] Mareck, U.; Sigmund, G.; Opfermann, G.; Geyer, H.; Thevis, M.; Schänzer, W.; Rapid. Commun. Mass. Spectrom. 2005, 19, 3689–3693.
• [39] Beer, B.; Schubert, B.; Oberguggenberger, A.; Meraner, V.; Hubalek, M.; Oberacher, H. Anal. Bioanal.
• [40] Mazzarin, M.; Botrè, F. Rapid. Commun. Mass. Spectrom. 2006, 20, 3465–3476.
• [41] Kang, M.; Hwang, Y.; Lee, W.; Kim, D. Rapid. Commun. Mass. Spectrom. 2007, 21, 252–264.
• [42] Shao, R.; Yu, L.; Lou, H.; Ruan, Z.; Jiang, B.; Chen, J. J. Biomed. Chromatogr. 2016, 30, 632–637.
• [43] Platova, A.; Miroshnichenko, I.; Ptitsina, S.; Yurchenko, N. Pharm. Chem. J. 2014, 48, 292–297.
• [44] Precht, J.; Ganchev, B.; Heinkele, G.; Brauch, H.; Schwab, M.; Mürdter, T. Anal. Bioanal. Chem. 2012, 403, 301–308.
• [45] Rodriguez-Mozaz, S.; Lopez de Alda, M.; Barceló, D. J. Chromatogr. A 2007, 1152, 97–115.
• [46] Shi, X.; Fan, T.; Yao, J. J. Hebei Univ. Sci. Technol. 2017, 38, 375–382.
• [47] Kallepalli, P.; Annapurna, M. Int. J. Green. Pharm. 2018, 12, S270.
• [48] Sreelakshmi, M.; Sasidhar, R.; Raviteja, B. Invent. Rapid. Pharm. Anal. Qual. Assur. 2019, 2, 1–7.
• [49] Wang, L.; Qiu, F.; Song, W.; Wang, Z. Chin, J. New Drug 2017, 26, 2468–2471.
• [50] Shanghai Centre ; Guangzhou Univ. Chin. J. Pharm. 2018, 49, 205–211.
• [51] Nalanda, R.; Srinivasa, A.; Gowri, D. Int. J. Pharm. Sci. Res. 2018, 9, 3883–3888.
• [52] Tamura, K.; Mukai, M.; Naito, Y.; Yonemori, K.; Kodaira, M.; Tanabe, Y.; Yamamoto, N.; Osera, S.; Sasaki, M.; Mori, Y.; Hashigaki, S.; Nagasawa, T.; Ko Umeyama, Y.; Yoshino, T. Cancer Sci. 2016, 107, 75.
• [53] Nguyen, L.; Zhong, W.; Painter, C.; Zhang, C.; Rahavendran, S.; Shen, Z. J. Pharm. Biomed. Anal. 2010, 53, 228–234.
• [54] Smith, D.; Tella, M.; Rahavendran, S.; Shen, Z. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879, 2860–5.
• [55] Dange, Y.; Bhinge, S.; Salinkhe, V. J. Toxicol. Mech. method 2018, 28, 187–194.
• [56] Polson, C.; Sarkar, P.; Incledon, B.; Raguvaran, V.; Grant, R. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 785, 263–275.
• [57] Miller, J. C., and Miller, J. N., Statistics for Analytical Chemistry, 2nd Ed., Ellis Horwood, Chichester, England, 2005.
• [58] Guidance for Industry Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, 2001.
• [59] The guidelines for care and use of experimental animals by the Committee for Purpose of Control and Supervision on Experiments on Animals (CPCSEA), 2003.
• [60] Guide laboratory animals for the care and use of 8th ed. committee for the update of the guide for the care and use of laboratory animals Institute for laboratory animal research Division on earth and life studies, The National Academy of Sciences, USA, 2011.

Uwagi

PL

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).